The market for anti-obesity drugs in India has seen remarkable growth, surging from ₹133 crore in March 2021 to an impressive ₹576 crore by March 2025. This increase is driven by the rise in lifestyle diseases and a growing willingness among people to invest in weight-loss treatments, according to industry tracker PharmaTrac.
A major player in this expansion is semaglutide, available as the pill Rybelsus, which contributes a staggering 69% of the market share. Just a year ago, Rybelsus accounted for only ₹11 crore, showcasing extraordinary growth. Another significant addition is Eli Lilly’s Mounjaro, a weekly injectable designed for weight management and type 2 diabetes. Priced at ₹3,500 per dose, Mounjaro appears to be an attractive option for many looking to manage their weight effectively.
New advancements in obesity treatment are noteworthy. Novo Nordisk is planning to introduce its injectable semaglutide, Wegovy, which is anticipated to bring additional benefits, including improvements in cardiovascular health for Indian patients. The arrival of these newer therapies suggests a shift in how obesity is treated, moving towards more effective solutions.
“Rybelsus has really driven growth in this market, and Mounjaro is likely to boost that even further,” says Sheetal Sapale, VP at PharmaTrac. She emphasizes that the rising prevalence of lifestyle-related diseases and the willingness to pay for treatment creates a vibrant market for anti-obesity drugs.
These medications work primarily by making individuals feel full for longer periods, but for lasting results, they must be used alongside lifestyle changes. Other drugs in the market include orlistat, dulaglutide, and liraglutide, which also offer varying degrees of effectiveness.
Obesity is a critical issue in India, affecting around 100 million adults. This condition is linked to serious health risks, such as type 2 diabetes and hypertension, highlighting the need for effective treatments. As the sector matures, more awareness and evolving treatment protocols are expected to drive growth.
Global trends support this optimism. New therapies like semaglutide and Mounjaro also help manage blood sugar levels, signaling a comprehensive approach to treating obesity. Bhanu Prakash Kalmath SJ, a healthcare industry leader, notes that the introduction of these treatments marks a significant change in obesity management in India.
In summary, the anti-obesity drug market in India is on a promising path, driven by innovative treatments and greater public awareness of obesity’s risks and solutions. As new options continue to emerge, the future looks brighter for effective weight management in the country. For more detailed insights into the global obesity treatment landscape, you can visit World Health Organization.
Check out this related article: Indulge in Free Ice Cream: Your Ultimate Guide to Ben & Jerry’s Free Cone Day!
Source linkanti-obesity drug market India,semaglutide Rybelsus,Mounjaro tirzepatide,lifestyle diseases India,Novo Nordisk,obesity drugs efficacy,Eli Lilly,weight-loss treatment India,adult obesity statistics India,chronic weight management
